Jan 7, 2026 01:01AM
Aug 8, 2025 08:23AM
Aug 8, 2024 05:51PM
Jun 20, 2024 07:20AM
Jun 20, 2024 07:20AM
Jun 18, 2024 01:10PM
May 21, 2024 07:15AM SAB Biotherapeutics (SABS) Announces FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
May 21, 2024 07:15AM
Nov 29, 2023 07:30AM
Nov 14, 2023 07:30AM
Oct 19, 2023 07:30AM
Oct 19, 2023 07:30AM
Apr 26, 2023 08:30AM
Apr 26, 2023 08:30AM SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
Apr 18, 2023 08:32AM
Apr 18, 2023 08:30AM
Apr 13, 2023 08:31AM
Apr 13, 2023 08:30AM
Jan 10, 2023 08:00AM
Jan 10, 2023 08:00AM
Nov 21, 2022 08:15AM SAB Biotherapeutics (SABS) Initiates IND-Enabling GLP Toxicology Study for SAB-142
Nov 21, 2022 08:14AM
Nov 21, 2022 08:14AM
Aug 9, 2022 04:30PM
Mar 2, 2022 06:00AM
Mar 2, 2022 06:00AM
Mar 2, 2022 06:00AM
Mar 2, 2022 05:53AM SAB Biotherapeutics (SABS) Reports Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants
Mar 1, 2022 07:30PM
Jan 24, 2022 06:00AM
Jan 24, 2022 06:00AM
Jan 24, 2022 06:00AM
Dec 16, 2021 06:01AM
Dec 16, 2021 06:00AM
Dec 16, 2021 06:00AM SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
Oct 25, 2021 07:39AM
Oct 25, 2021 07:39AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All